Blood Res 2017; 52(1):
Published online March 27, 2017
https://doi.org/10.5045/br.2017.52.1.44
© The Korean Society of Hematology
1Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
2Comprehensive Cancer Center, Médica Sur Clinic and Foundation, Mexico City, Mexico.
Correspondence to : Hernandez-Company Alonso, M.D. Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Tlalpan, Mexico City 14080, Mexico. retriever_g@yahoo.com
Autoimmune hemolytic anemia (AIHA) is characterized by an autoimmune-mediated destruction of red blood cells. Warm AIHA (wAIHA) represents 60% of AIHA cases and is associated with the positive detection of IgG and C3d in the direct antiglobulin test (DAT). This study aimed to assess the clinical and laboratorial differences between primary and secondary wAIHA patients from a referral center in Mexico City.
All patients diagnosed with wAIHA in our institution from January 1992 to December 2015 were included and received corticosteroids as the first-line treatment. We analyzed the response to the first-line treatment, relapse-free survival, and time to splenectomy.
Eighty-nine patients were included. Secondary wAIHA represented 55.1% of the cases. At diagnosis, secondary wAIHA patients showed a DAT mixed pattern more frequently than primary wAIHA patients (36.7 vs. 17.5%,
Secondary wAIHA may benefit from a longer low-dose steroid maintenance period mainly due to its shorter time to relapse and time to splenectomy than primary wAIHA.
Keywords Autoimmune hemolytic anemia, Warm autoimmune hemolytic anemia, Primary wAIHA, Secondary wAIHA, Direct antiglobulin test
Blood Res 2017; 52(1): 44-49
Published online March 27, 2017 https://doi.org/10.5045/br.2017.52.1.44
Copyright © The Korean Society of Hematology.
Hernandez-Company Alonso1*, Anguiano-Alvarez Victor Manuel1, Carmona Gonzalez Carlos Amir2, Rodriguez-Rodriguez Sergio1, Pomerantz Allan1, Lopez-Karpovitch Xavier1, and Tuna-Aguilar Elena Juventina1
1Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
2Comprehensive Cancer Center, Médica Sur Clinic and Foundation, Mexico City, Mexico.
Correspondence to: Hernandez-Company Alonso, M.D. Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Tlalpan, Mexico City 14080, Mexico. retriever_g@yahoo.com
Autoimmune hemolytic anemia (AIHA) is characterized by an autoimmune-mediated destruction of red blood cells. Warm AIHA (wAIHA) represents 60% of AIHA cases and is associated with the positive detection of IgG and C3d in the direct antiglobulin test (DAT). This study aimed to assess the clinical and laboratorial differences between primary and secondary wAIHA patients from a referral center in Mexico City.
All patients diagnosed with wAIHA in our institution from January 1992 to December 2015 were included and received corticosteroids as the first-line treatment. We analyzed the response to the first-line treatment, relapse-free survival, and time to splenectomy.
Eighty-nine patients were included. Secondary wAIHA represented 55.1% of the cases. At diagnosis, secondary wAIHA patients showed a DAT mixed pattern more frequently than primary wAIHA patients (36.7 vs. 17.5%,
Secondary wAIHA may benefit from a longer low-dose steroid maintenance period mainly due to its shorter time to relapse and time to splenectomy than primary wAIHA.
Keywords: Autoimmune hemolytic anemia, Warm autoimmune hemolytic anemia, Primary wAIHA, Secondary wAIHA, Direct antiglobulin test
Time to response to the first-line treatment in patients with primary and secondary wAIHA.
Differences in relapse-free survival between primary and secondary AIHA.
Time-to-splenectomy in patients with primary and secondary AIHA.
Table 1 . Demographics and clinical characteristics of patients with AIHA..
Table 2 . Clinical severity at onset and wAIHA relationship with DAT and transfusion requirements..
Raghuveer Prabhu, Renjitha Bhaskaran, Veena Shenoy, Rema G, and Neeraj Sidharthan
Blood Res 2016; 51(2): 88-94José Carlos Jaime-Pérez, Patrizia Aguilar-Calderón, Lorena Salazar-Cavazos, Andrés Gómez-De León, David Gómez-Almaguer
Blood Res 2019; 54(2): 131-136Víctor Manuel Anguiano-Álvarez, Alonso Hernández-Company, Nashla Hamdan-Pérez, Daniel Montante-M, Diego A. Zúñiga-Tamayo, Sergio Rodríguez-Rodríguez, Alan Pomerantz, and Elena J. Tuna-Aguilar
Blood Res 2018; 53(1): 35-40
Time to response to the first-line treatment in patients with primary and secondary wAIHA.
|@|~(^,^)~|@|Differences in relapse-free survival between primary and secondary AIHA.
|@|~(^,^)~|@|Time-to-splenectomy in patients with primary and secondary AIHA.